Apollo AyurVAID Unveils India's First Clinically-Tested Ayurveda Line

Apollo AyurVAID, a part of Apollo Hospitals Group, has announced the launch of India’s First line of “Tested Safe” Ayurveda products, setting a new benchmark in the traditional medicine space. The line includes classical prescription formulations, over-the-counter wellness products, and medical foods.

Each product has been put through extensive safety testing at NABL-accredited labs for heavy metals, aflatoxins, microbial load, etc. Each product pack will include a QR code to trace detailed test reports, so consumers can expect total transparency for each product.

With an initial investment of Rs 15 crore, Apollo AyurVAID is planning to grow the product portfolio to 50 SKUs targeting important health segments like pain management, stress, sleep, skin care. Products will be sold through Apollo pharmacies, AyurVAID hospitals, Apollo 24|7, and major e-commerce websites.

Also Read: Phytopharmaceuticals: Driving Global Herbal Medicine Innovation

Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals and Chairperson, Apollo AyurVAID said, “Apollo AyurVAID’s foray into tested-safe Ayurveda products marks a key step in redefining standards of safety, transparency, and effectiveness in traditional medicine. This expansion builds on a strong foundation of clinical excellence and shows our deep commitment to evidence-based, precision Ayurveda. By blending innovation with time-tested wisdom, Apollo AyurVAID is shaping the future of integrative medicine in India and beyond.”

Apollo also is launching a second line of botanical supplements called AvestaAyurVAID, in partnership with biotechnology company Avesthagen, further incorporating modern science to connect Ayurvedic knowledge with natural variables, without additives and sugars.

Looking to the future, Apollo AyurVAID hopes to grow to 18 clinical centres with a total of 350 beds, increasing treatment capacity to over 50,000 patients annually. The company is targeting Rs 100 crore in annual revenue by FY26, with an ambitious goal of reaching Rs 500 crore within five years, redefining how Ayurveda is delivered and trusted in modern India.